Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-00420 vs chemotherapy in FGFR2-altered intrahepatic cholangiocarcinoma (post first-line)
CTR20255200Phase 3Active
- Sponsor
- TransThera Biosciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tinengotinib in intrahepatic cholangiocarcinoma (ICC), sponsored by TransThera Biosciences. Started Apr 2026; status: active.
02
Drugs
tinengotinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20255200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255200.